An isoxazoline-substituted benzamide compound, and the salt thereof. For example, a compound having the following formula:

##STR00001##

and pesticides characterized by containing the compound as an active ingredient.

The present disclosure provides an immunogenic composition comprising an emulsion of an epitope or a nucleic acid molecule. The emulsion comprises an oil phase and a water phase. The emulsion is an oil-in-water emulsion and/or a nanoemulsion. The epitope is present on a peptide or a polypeptide derived from Schistosoma sp. and can optionally be glycosylated. The immunogenic composition (which can be provided as a pharmaceutical composition or as a vaccine) can be used to prevent, treat or alleviation the symptoms of a Schistosoma sp. infection.

The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.

The application is directed to in vitro-reared Plasmodium sporozoites of human host range wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same. Provided herein are in vitro-reared infectious Plasmodium sporozoites (SPZ) of human host range, particularly P. falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi, wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same.

The present disclosure provides a corn position of artesunate, a process of preparing the same, and a method of treatment.

A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a patient infected with pathogenic organisms; wherein X and Y are each independently selected from C, N, O and S, provided at least one of X and Y is N, O or S; wherein R.sup.1 and R.sup.2 are each independently selected from an optionally substituted C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkenyl, aryl, heteroaryl or alkylaryl group; and wherein Z is selected from H, —CN, —NO.sub.2, —NR.sup.3R.sup.4, —NR.sup.5(CO)R.sup.6; C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, —(CO)WR.sup.12, hydroxy, amino, thiol, chloro, fluoro, CF.sub.3, CHF.sub.2 or CH.sub.2F groups. The compounds may be effective in treating patients/animals infected with parasites selected from Schistosoma, Haemonchus, Eimeria, Echinococcus, Dirofilaria, Fasciola or Plasmodium parasites. Additionally or alternatively, the compounds of formula (I) may be effective in treating patients infected with pathogenic bacteria selected from S. aureus, MRSA and Enterococcus faecalis.

A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a patient infected with pathogenic organisms; wherein X and Y are each independently selected from C, N, O and S, provided at least one of X and Y is N, O or S; wherein R.sup.1 and R.sup.2 are each independently selected from an optionally substituted C.sub.1-C.sub.8 alkyl, C.sub.1-C.sub.8 alkenyl, aryl, heteroaryl or alkylaryl group; and wherein Z is selected from H, —CN, —NO.sub.2, —NR.sup.3R.sup.4, —NR.sup.5(CO)R.sup.6; C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 alkoxy, —(CO)WR.sup.12, hydroxy, amino, thiol, chloro, fluoro, CF.sub.3, CHF.sub.2 or CH.sub.2F groups. The compounds may be effective in treating patients/animals infected with parasites selected from Schistosoma, Haemonchus, Eimeria, Echinococcus, Dirofilaria, Fasciola or Plasmodium parasites. Additionally or alternatively, the compounds of formula (I) may be effective in treating patients infected with pathogenic bacteria selected from S. aureus, MRSA and Enterococcus faecalis.

The present invention refers to a pharmaceutical preparation (10) comprising a first pharmaceutical composition having a matrix material and pharmaceutically active ingredients distributed within the matrix material, wherein the first pharmaceutical composition comprises Praziquantel, Pyrantel and Febantel as pharmaceutical active ingredients, wherein the preparation (10) comprises a second pharmaceutical composition having a matrix material and at least one of avermectins and milbemycins such as Moxidectin as pharmaceutically active ingredient distributed within the matrix material, wherein the preparation (10) is provided in a multi-layer structure such, that the first composition is provided in a first layer (12) and the second composition is provided in a second layer (14), wherein the first layer (12) and the second layer (14) are separated by a barrier layer (16) being provided between the first layer (12) and the second layer (14).

A soft chewable pharmaceutical product for delivery of a pharmaceutically acceptable active ingredient to an animal comprising pamoic acid or a pharmaceutically acceptable salt and a process for the manufacture of such soft chewable pharmaceutical product.

The invention provides compositions comprising mesenchymal stem cell (MSC) derived exosomes, and methods of their use in subjects having certain lung diseases including inflammatory lung disease.